双参数磁共振成像检测外周带PIRADS 3病灶中临床显著前列腺癌的患病率:本地经验
研究纳入2022年1月至12月间接受双参数MRI且外周带发现PIRADS 3病灶的患者,61/688例(8.8%)符合条件,58例接受局麻经会阴穿刺活检,临床显著前列腺癌(Gleason评分≥3+4且最大癌芯长度≥6 mm)检出率为17%。在确诊临床显著前列腺癌的患者中,80%的前列腺特异性抗原密度(PSAD)>0.15 ng/ml/cc,未报告活检后并发症。作者认为,不使用对比剂的双参数MRI可作为多参数MRI的可靠替代方案,对外周带PIRADS 3病灶中临床显著前列腺癌诊断影响最小或可忽略,尤其当结合PSAD等其他因素时。
要点
- 外周带PIRADS 3病灶在双参数MRI中占8.8%(61/688例),活检确诊临床显著前列腺癌者占17%。
- 确诊临床显著前列腺癌的患者中80% PSAD>0.15 ng/ml/cc。
- 未报告活检后并发症。
核心结论
- 不使用对比剂的双参数MRI可作为多参数MRI的可靠替代方案,对外周带PIRADS 3病灶中临床显著前列腺癌诊断影响最小或可忽略,尤其当结合PSAD等其他因素时。
- 作者认为,这有可能减轻前列腺癌检查中的卫生经济学负担和患者负担。
研究设计与样本
- 单中心回顾性研究,纳入2022年1月至12月间接受双参数MRI并在外周带诊断为PIRADS 3病灶的患者。
- 共688例MRI中61例(8.8%)外周带存在PIRADS 3病灶,其中58例接受局麻经会阴穿刺活检进行组织学分析。
- 所有患者均未接受动态对比增强。
- 参考标准为活检组织学,临床显著前列腺癌定义为Gleason评分≥3+4且最大癌芯长度≥6 mm。
- 同时回顾了前列腺特异性抗原密度(PSAD)和活检并发症发生率。
诊断标准与关键数值
- 临床显著前列腺癌定义:Gleason评分≥3+4且最大癌芯长度≥6 mm。
- 外周带PIRADS 3病灶在双参数MRI中的比例为8.8%(61/688例)。
- 活检确诊临床显著前列腺癌的检出率为17%(58例活检中)。
- 确诊临床显著前列腺癌的患者中80% PSAD>0.15 ng/ml/cc。
- 未报告活检后并发症。
临床应用与阅片要点
- 在外周带PIRADS 3病灶中,双参数MRI(不使用动态对比增强)对临床显著前列腺癌诊断的影响最小或可忽略。
- 作者认为,双参数MRI可结合PSAD等其他因素使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: The aim of this study was to determine whether biparametric magnetic resonance imaging (MRI) is effective in the diagnosis of clinically significant prostate cancer in prostate peripheral zone Prostate Imaging Reporting and Data System (PIRADS) 3 lesions without the use of dynamic contrast enhancement.
MATERIALS AND METHODS: Patients who underwent biparametric MRI over a 12-month period from January 2022 to December 2022 and were diagnosed with PIRADS 3 lesion in the peripheral zone were included in the study. No patient received dynamic contrast enhancement. Histological analysis was done after performing local anesthetic transperineal biopsy to determine detection rate of clinically significant prostate cancer. Prostate-specific antigen density (PSAD) and biopsy complication rates were also reviewed.
RESULTS: Sixty-one out of 688 MRIs (8.8%) performed over the study period had a PIRADS 3 lesion in the peripheral zone where contrast is supposed to add value. Fifty-eight of the 61 went ahead to biopsy, and csPCa (Gleason score: ≥3 + 4, with a max core length of ≥6 mm and above) was diagnosed in 17%. Among those diagnosed with csPCa, 80% had a PSAD of >0.15 ng/ml/cc. No postbiopsy complications were reported.
CONCLUSION: Biparametric MRI without contrast offers a reliable alternative to multiparametric MRI with minimum or neglible impact on clinically significant prostate cancer (csPCa) diagnosis in peripheral zone PIRADS 3 lesions, especially when used in conjunction with other factors such as PSAD. There is potential to address health economics and patient burden in prostate cancer investigation.
引用
- Khalid MJ, Parker P, Smith S, et al. Prevalence of clinically significant prostate carcinoma in Prostate Imaging Reporting and Data System (PIRADS) 3 lesions detected in the peripheral zone on biparametric magnetic resonance imaging (MRI)-a local experience. Clin Radiol. 2024. PMID: 39129105. doi:10.1016/j.crad.2024.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。